Peter Gardiner joins BG Medicine
This article was originally published in Clinica
Molecular diagnostics firm BG Medicine has made Peter Gardiner vice-president of medical affairs and senior medical officer. Dr Gardiner will be responsible for leading and co-ordinating research projects, clinical publications and presentations, as well as supporting the firm's clinical collaborators and research partners. He has 25 years' experience in the pharmaceutical and medical device industries, and previously worked for Bristol-Myers Squibb's medical imaging division as medical director of global medical affairs and senior medical officer. Before that, he was vice-president of medical affairs for DuPont's medical imaging business. Waltham, Massachusetts-based BG Medical is focused on biomarkers for cardiovascular disease, cancer and central nervous system disorders. Its tests are designed to predict a patient's response to drug therapy, determine the potential toxicity of drugs, identify patients at risk of developing certain diseases, predict patient prognosis, and monitor patients' disease progression or response to drugs.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.